Miami (August 28, 2025) – Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved ...
Nonmedication COPD strategies, such as pulmonary rehabilitation, are highlighted. Jeffrey D. Dunn, PharmD, MBA: [Summarize] the nonmedication strategies that we can use to optimize the management of ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. After things have been stable for a long ...
Readers were most interested in how pulmonary rehabilitation referrals and discharge disposition differ with vs. without use of an inpatient COPD clinical pathway embedded directly into the electronic ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.
The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and Informing the Pathway of Chronic ...
Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition, ...
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results